Table 1.
Parameters | High CASC9 Expression (≥ Mean, n=35) | Low CASC9 Expression (< Mean, n=59) | P-Value |
---|---|---|---|
Sex | |||
Male | 16 | 31 | 0.306 |
Female | 19 | 28 | |
Age | |||
≥55 | 21 | 32 | 0.372 |
<55 | 14 | 27 | |
Tumor diameter | |||
≥2 cm | 22 | 23 | 0.033* |
<2 cm | 13 | 36 | |
Differentiation | |||
Moderately/poorly | 15 | 36 | 0.133 |
Well | 20 | 23 | |
TNM stage | 0.049* | ||
I | 3 | 15 | |
II | 8 | 20 | |
III | 14 | 12 | |
III-IV | 10 | 12 | |
Lymph node metastasis | |||
With | 22 | 19 | 0.01* |
Without | 13 | 40 | |
Distant metastasis | |||
Yes | 22 | 25 | 0.044* |
No | 13 | 34 |
Note: The mean expression level was used as the threshold. For analysis of association between CASC9 levels and clinical features, Pearson’s χ2 tests were used *P<0.05.
Abbreviation: TNM, tumor node metastasis stage.